DSM Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-932,595	Closed	-$127M	–	43
2024 Q4	$127M	Sell	932,595 -11,559	-1%	-$1.43M	1.97%	17
2024 Q3	$109M	Sell	944,154 -53,630	-5%	-$7.35M	1.66%	18
2024 Q2	$137M	Sell	997,784 -138,218	-12%	-$19M	1.99%	17
2024 Q1	$157M	Sell	1,136,002 -86,007	-7%	-$11.7M	2.14%	16
2023 Q4	$161M	Sell	1,222,009 -2,008	-0.2%	-$231K	2.46%	15
2023 Q3	$138M	Buy	1,224,017 +163,747	+15%	+$17.2M	2.32%	14
2023 Q2	$100M	Sell	1,060,270 -199,261	-16%	-$19.5M	1.62%	24
2023 Q1	$127M	Sell	1,259,531 -73,172	-5%	-$7.61M	2.09%	23
2022 Q4	$159M	Buy	1,332,703 +10,501	+0.8%	+$1.23M	2.65%	13
2022 Q3	$140M	Sell	1,322,202 -9,258	-0.7%	-$939K	2.38%	15
2022 Q2	$130M	Sell	1,331,460 -19,871	-1%	-$1.83M	2.18%	14
2022 Q1	$127M	Sell	1,351,331 -56,866	-4%	-$4.82M	1.69%	23
2021 Q4	$120M	Sell	1,408,197 -104,913	-7%	-$9.65M	1.26%	26
2021 Q3	$145M	Sell	1,513,110 -22,374	-1%	-$2.11M	1.51%	21
2021 Q2	$149M	Buy	1,535,484 +186,977	+14%	+$17.9M	1.44%	25
2021 Q1	$131M	Buy	1,348,507 +232,127	+21%	+$24.3M	1.4%	23
2020 Q4	$107M	Buy	1,116,380 +279,614	+33%	+$27M	1.15%	25
2020 Q3	$80.5M	Sell	836,766 -28,848	-3%	-$3.34M	0.89%	24
2020 Q2	$106M	Buy	865,614 +5,561	+0.6%	+$615K	1.26%	21
2020 Q1	$74.4M	Buy	860,053 +189,504	+28%	+$18.5M	1.13%	24
2019 Q4	$72.1M	Buy	670,549 +19,336	+3%	+$2.02M	0.95%	29
2019 Q3	$58.7M	Sell	651,213 -9,311	-1%	-$870K	0.9%	28
2019 Q2	$55.8M	Sell	660,524 -35,658	-5%	-$2.93M	0.81%	28
2019 Q1	$61.3M	Buy	+696,182	New	+$58.2M	0.9%	29